Abstract
Dopamine (DA) disruption is implicated in the neuropathology of multiple brain disorders (schizophrenia, addiction, attention deficit hyperactivity disorder, Parkinson disease) and it is the main target of antipsychotics, stimulants, and antiparkinson medications. Although with PET and single-photon emission computed tomography one can measure DA signaling in the human brain, the application of these methodologies has been limited by its cost (PET), limited access to radiotracers, and the restrictions imposed by the use of radiation. Thus, alternative imaging modalities that overcome these limitations could expand their utilization in clinical research and would bring us closer to a more accessible biomarker for assessing brain DA activity in the clinical setting. In PNAS, Sander et al. (1) demonstrate a dynamic coupling between DA D2 receptor (D2R) occupancy level, a marker of DA neurotransmission, and the concomitant regional cerebral blood volume (rCBV) changes in the primate brain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
